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Objectives: Several clinical trials conducted in Europe and US reported favorable outcomes of patients with
APL treated with the combination of all trans retinoic acid (ATRA) and anthracyclines. Nevertheless, the
results observed in developing countries with the same regimenwas poorer, mainly due to high early mortality
mainly due bleeding. The International Consortium on Acute Promyelocytic Leukemia (IC-APL) is an initiative
of the International Members Committee of the ASH and the project aims to reduce this gap through the
establishment of international network, which was launched in Brazil, Mexico and Uruguay.
Methods: The IC-APL treatment protocol is similar to the PETHEMA 2005, but changing idarubicin to
daunorubicin. All patients with a suspected diagnosis of APL were immediately started on ATRA, while
bone marrow samples were shipped to a national central lab where genetic verification of the diagnosis
was performed. The immunofluorescence using an anti-PML antibody allowed a rapid confirmation of the
diagnosis and, the importance of supportive measures was reinforced.
Results: The interim analysis of 97 patients enrolled in the IC-APL protocol showed that complete remission
(CR) rate was 83% and the 2-year overall survival and disease-free survival were 80% and 90%,
respectively. Of note, the early mortality rate was reduced to 7.5%.
Discussion: The results of IC-APL demonstrate the impact of educational programs and networking on the
improvement of the leukemia treatment outcome in developing countries.
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Acute promyelocytic leukemia (APL) is characterized
by a massive infiltration of bone marrow by heavily
granulated blasts that resemble promyelocytes and
harbor balanced reciprocal translocations between
chromosomes 15 and 17. The t(15;17) is detected in
about 98% of patients with APL; it results in the
formation of a fusion gene containing large sequences
of the genes RARalpha and PML, localized on
chromosomes 17 and 15, respectively. The expression
of the oncoprotein PML–RARalpha is the basic
leukemogenic event of APL.1 Other chromosomal
translocations, such as t(11;17) and t(5;17), are detected
in less than 5% of cases of APL.2 PML–RARalpha
expression results in maturation arrest of myeloid cells
in the promyelocytic phase. In short, PML–RARalpha
forms homodimers that retain the functional domains
of both proteins, bind to RARalpha targets, and
repress their function by the recruitment of co-
repressors. The end result is a block of cell differentia-
tion and increased resistance to apoptosis.1
Douer et al.3 were the first to report a higher
incidence of APL in patients with ‘Latino’ and ‘non-
Latino’ ancestry. Further studies based on hospital
registries as well as population-based analysis suggested
that the Latino population have shown that APL
incidence ranged from 20% to 37.5% against 6–12% in
Latino and non-Latino populations, respectively. We
have reported that APL represents 28.2% of all acute
myeloid leukemia (AML) cases in centers in Brazil,4 a
number that is very similar to the reported by Melo
et al. (28%).5 Similar results were reported by studies
performed in Mexico (20%),6 Venezuela (27.8%),7 and
Peru (22%).8 Moreover, the higher APL frequency was
also reported among children from Latin America,
despite the fact that APL is less common in this age
group.9 The higher APL frequency may be due to the
age distribution of the population, since APL is known
to be more frequent among young adults, whereas the
incidence of the other AML subtypes increases with
age. In fact, an Italian study demonstrated that the
incidence of APL in patients aging from 15 to 24 years
was 27.7%, and among those older than 75 years, it was
only 2.7%.10 One may also argue that the difference in
incidence between Latino and non-Latino populations
is due to the lower frequency of APL in Northern
Europe compared to Mediterranean countries, and
consequently in their former colonies in America. In
this regard, studies carried out in UK11 and in
Scandinavian12 countries indicated that APL repre-
sented about 10% of all AML cases.
The introduction of the all-trans-retinoic acid
(ATRA) in the treatment of APL changed one of
the most lethal subtypes of leukemia into a highly
curable disease.13 But ATRA when used alone results
in short lasting complete remissions in most cases,
and the standard of care is considered to be the
combination of ATRA and anthracyclines. This
combination results in extremely high antileukemic
efficacy, leading to complete remission (CR) in 90–95%
of patients, and primary resistance has been only
reported in just a few anecdotal cases.14 The majority
of centers in Latin America adopt protocols based on
ATRA plus anthracyclines, similar to those reported
by the Italian GIMEMA or the Spanish PETHEMA
groups.14–16 Nevertheless, the outcome of APL treat-
ment in developing countries is poorer than that
reported in the USA and Europe mainly due to high
early mortality mainly due bleeding.4,17 We have
analyzed the outcome of 134 Brazilian patients treated
with antracycline plus ATRA-based therapy between
January 2003 and March 2006 at 12 institutions. The
induction mortality was as high as 32.1% and bleeding
was the cause of death in 60.5% of the cases. Even
during consolidation, we observed a mortality rate of
10.5%, and mortality was mainly due to bleeding
(21.4%), infection (28.6%), or their association (14.3%).
The cumulative mortality was 44.7%.4 In order to
improve treatment outcome of APL patients in deve-
loping countries, the American Society of Hematology
sponsored the creation of the International Consor-
tium on Acute Promyelocytic Leukemia (IC-APL).
The protocol is similar to the PETHEMA 2005,18 but
changing idarubicin to daunorubicin. Furthermore, the
adoption of the immunofluorescence using an anti-
PML antibody allowed a rapid confirmation of the
diagnosis (,4 hours).19 The importance of supportive
measures was reinforced. These consisted mainly in the
transfusion of fresh frozen plasma, fibrinogen, and/or
cryoprecipitate and platelet transfusions to maintain
the fibrinogen concentration and platelet count above
100–150 mg/dl and 30–506109/l, respectively, which
should be monitored at least once a day.13 We recently
reported preliminary data from 97 patients included in
the IC-APL 2006 protocol.20 There was a remarkable
improvement in survival that reached 75% in 1 year
and the disease-free survival in the same period was
95%. Furthermore, there was an improvement in early
mortality which was reduced to 7.5%.20 The results of
IC-APL demonstrate the impact of educational pro-
grams and networking on the improvement of the
leukemia treatment outcome in developing countries.
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